Mitchell Shiffman, MD
Enriched profileDirector, Liver Institute of Virginia (Bon Secours Mercy Health); Professor of Medicine, Eastern Virginia Medical School · Liver Institute of Virginia
Mitchell Shiffman is Director, Liver Institute of Virginia (Bon Secours Mercy Health); Professor of Medicine, Eastern Virginia Medical School at Liver Institute of Virginia. OpenAlex indexes 402 publications with 54,249 citations (h-index 98); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Gastroenterology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 13 Oct 2026
Mitchell L. Shiffman, MD, is Director, Liver Institute of Virginia (Bon Secours Mercy Health). The public record shows 402 publications with 54,249 citations (h-index 98), centered on Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 32 companies, 3 NIH-funded awards (1991–2010).
- Most recent indexed publication: 2024 · Alimentary pharmacology & therapeutics
- Top research focus: Hepatitis C virus research
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 32 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 249.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Participant
FDA Gastrointestinal Drugs Advisory Committee meeting on obeticholic acid (Ocaliva) for primary biliary cholangitis, September 13
2024provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →fda.gov ↗ - Guest Editor
Clinics in Liver Disease, 2021 Volume 25-4, 'Challenging Issues in the Management of Chronic Hepatitis B Virus'
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)
Sponsor: Liver Institute of Virginia
- Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
Sponsor: Romark Laboratories L.C.
Industry payments
Updated 13 Oct 2026
32 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Ipsen Biopharmaceuticals, IncProgram year202523 payments$56,587openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year202520 payments$44,635openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year202529 payments$26,965openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
37.8%Aldosterone antagonist (MRA)19.3%Spironolactone100%Part D≥48 patientsLoop diuretic16.1%Furosemide100%Part D≥49 patients+ 1 more class in this area
Metabolism & gastrointestinal
34.3%Rifamycin Antibacterial10.9%Xifaxan100%Part D≥18 patientsOsmotic Laxative7.8%Lactulose100%Part D≥21 patients+ 3 more classes in this area
Anti-infectives
9.8%Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor9.8%Epclusa74%Sofosbuvir-Velpatasvir26%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
3 NIH research awards on record, funded 1991–2010 per NIH RePORTER. The latest:
- ANCILLARY STUDY TO THE HALT-C ANTI-VIRAL LONG-TERM TREATMENT AGAINST CIRRHOSI
Virginia Commonwealth University
FY2010$1,289M01RR000065 - CLINICAL TRIAL: HEP C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C)
Virginia Commonwealth University
FY2009$196,411M01RR000065 - ANCILLARY STUDY TO THE HALT-C ANTI-VIRAL LONG-TERM TREATMENT AGAINST CIRRHOSI
Virginia Commonwealth University
FY2009$466M01RR000065
Congress activity
Updated 13 Oct 2026
1 congress contribution (2019) across ADA per OpenAlex. The most recent:
- 1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH)
ADA Scientific Sessions
ADA2019Co-authorPoster
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Alimentary pharmacology & therapeutics
Article2024 - Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hepatology (Baltimore, Md.)
Clinical Trial2023
Most-cited works
by citation count (OpenAlex)Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/mitchell-l-shiffman-446615166
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/mitchell-shiffman-b5549516
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- X / Twitter
aasld.confex.com/aasld/2023/meetingapp.cgi/Person/182692
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aasld.confex.com ↗ - Other
blog.bonsecours.com/healthy/hepatitis-information-doctor-profile-virginia
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.bonsecours.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctor.webmd.com ↗
- Board Certified
Internal Medicine, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctor.webmd.com ↗
Editorial & leadership roles
journal and society appointments- Director
Liver Institute of Virginia / Liver Institute of Richmond / Liver Institute of Hampton Roads, Bon Secours Mercy Health
2010verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗ - Professor of Medicine
Eastern Virginia Medical School, Norfolk, VA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
Secondary affiliations
appointments beyond the home institution- Former Chief
Hepatology Section, and Medical Director, Liver Transplant Program, VCU Medical Center, Richmond, VA
2009verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
Media & interviews
press, podcasts and appearances- ACG 'Video of the Week': Mitchell Shiffman
MD, FACG, on the Impact of Curing HCV, from 2015 ACG Hepatitis School
2015 - HCPLive video interview: 'Mitchell Shiffman
MD: Current Alcohol-Associated Hepatitis Care, Larsucosterol's Potential'
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com ↗ - HCPLive video interview: 'Mitchell Shiffman
MD: Phase 2b AHFIRM Data for Larsucosterol in Alcohol-Associated Hepatitis'
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →blog.bonsecours.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Charles Rice, MD
The Rockefeller University
Kris Kowdley, MD
Washington State University
Eamonn Quigley, MD
Houston Methodist Hospital and Academic Institute
Patrick Kamath, MD
Mayo Clinic